Sec SPDR Health-SBI (XLV)
$147.24
0.23 (0.16%)
XLV Stock Quote Delayed 30 Minutes
Are You Missing the Biotech Boat?
Biotech stocks have been one of the market's best performing areas during the past year and beyond. Is it too late to catch this comet?
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$146.92
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
8.01M
Day's Range
$146.51 - $147.64
52-Week Range
$135.33 - $156.55
Dividend & Yield
$1.77 (1.20%)
XLV Stock Predictions, Articles, and Sec SPDR Health-SBI News
What Sectors Will Work in QE3?
Market performance following past quantitative easing announcements might provide a clue as to which sectors will perform best in the month ahead.
Divided, This Rally Cannot Stand!
The fact that Thursday's rally was restricted to just several sectors following a breakout means a slight correction could be due. Watch for new entry points.
Utilities: Back to Hero, or Villain in Disguise?
This may be a temporary period of strength or a final move before a breakdown. A downtrend could be quite telling about the second half for equities.
5 Stocks to Avenge a Bad Court Ruling
Healthcare stocks are a good play right now to take advantage of pockets created by the recent Supreme Court ruling. Here are 5 to start with for investors.
A Ruling That’s Good for Health Care Stocks
A $2.7 trillion industry representing 18% of the economy now knows where it's headed. Losing the individual mandate would have been a worst-case scenario for it.
Where’s the Line in the Sand for This Selloff?
The Select Sector Energy SPDR might be the most important security to help you determine how long this market correction can continue.
Where to Find Opportunities in the Summer Doldrums
Take a look at which sectors have outperformed in the summer months during the past 10 years, and which have lagged. The results might surprise you.
Investors’ Blueprint for Another Euro-Crisis
Election results in France and Greece indicate the European debt crisis might again haunt the markets. Here are three opportunities for investors.
Why Biotech Investing Is So Hard
It spikes wildly when gaining, plunges quickly when falling -- and normal strategies don't apply.
The Best S&P Sectors for Q1
Not surprisingly, eight of the nine S&P sector ETFs followed the index higher in Q1 2012. Here's a look at how they all shook out -- and which ETF fell flat.
XLV Provides a Healthy Dose of Pfizer
If the health care sector is a must-have for your portfolio, and Pfizer is at the top of that list -- here's a way to get a healthier dose.
5 ETFs to Buy for Growth in 2012
Bets on leveraged debt and Treasuries were the golden ETFs of 2011 -- here are the funds investors should buy for 2012.
How to Profit From the Biggest Crises of 2012
It's one thing to expect things to go south, but plan the right trading strategy in advance and you'll have the upper hand. Consider these three moves.
